Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD)

Abstract

Benzoporphyrin derivative monoacid ring A (BPD-MA, verteporfin) is currently under investigation as a photosensitizer for photodynamic therapy (PDT). Since BPD exhibits rapid pharmacokinetics in plasma and tissues, we assessed damage to tumour and muscle microvasculature when light treatment for PDT was given at short times after injection of photosensitizer. Groups of rats with chondrosarcoma were given 2 mg kg(-1) of BPD intravenously 5 min to 180 min before light treatment of 150 J cm(-2) 690 nm. Vascular response was monitored using intravital microscopy and tumour cure was monitored by following regrowth over 42 days. For treatment at 5 or 30 min after BPD injection, blood flow stasis was limited to tumour microvasculature with lesser response in the surrounding normal microvasculature, indicating selective targeting for damage. No acute changes were observed in vessels when light was given 180 min after BPD injection. Tumour regression after light treatment occurred in all animals given PDT with BPD. Long-term tumour regression was greater in animals treated 5 min after BPD injection and least in animals given treatment 180 min after drug injection. The correlation between the timing for vascular damage and cure implies that blood flow stasis plays a significant role in PDT-induced tumour destruction.

References 23

1. 1.

   Allison B. A., Crespo M. T., Jain A. K., Richter A. M., Hsiang Y. N., Levy J. G. Delivery of benzoporphyrin derivative, a photosensitizer, into atherosclerotic plaque of Watanabe heritable hyperlipidemic rabbits and balloon-injured New Zealand rabbits. Photochem Photobiol. 1997;65(5):877-883.

   Not in our library10.1111/j.1751-1097.1997.tb01938.x

2. 2.

   Allison B. A., Pritchard P. H., Levy J. G. Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative. Br J Cancer. 1994;69(5):833-839.

   Not in our library10.1038/bjc.1994.162

3. 3.

   Allison B. A., Waterfield E., Richter A. M., Levy J. G. The effects of plasma lipoproteins on in vitro tumor cell killing and in vivo tumor photosensitization with benzoporphyrin derivative. Photochem Photobiol. 1991;54(5):709-715.

   Not in our library10.1111/j.1751-1097.1991.tb02079.x

4. 4.

   Chowdhary R. K., Ratkay L. G., Neyndorff H. C., Richter A., Obochi M., Waterfield J. D., Levy J. G. The use of transcutaneous photodynamic therapy in the prevention of adjuvant-enhanced arthritis in MRL/lpr mice. Clin Immunol Immunopathol. 1994;72(2):255-263.

   Not in our library10.1006/clin.1994.1139

5. 5.

   Fielding P. E., Vlodavsky I., Gospodarowicz D., Fielding C. J. Effect of contact inhibition on the regulation of cholesterol metabolism in cultured vascular endothelial cells. J Biol Chem. 1979;254(3):749-755.

   Not in our library

6. 6.

   Fingar V. H., Henderson B. W. Drug and light dose dependence of photodynamic therapy: a study of tumor and normal tissue response. Photochem Photobiol. 1987;46(5):837-841.

   Not in our library10.1111/j.1751-1097.1987.tb04856.x

7. 7.

   Fingar V. H., Wieman T. J., Doak K. W. Role of thromboxane and prostacyclin release on photodynamic therapy-induced tumor destruction. Cancer Res. 1990;50(9):2599-2603.

   Not in our library

8. 8.

   Fingar V. H., Wieman T. J., Wiehle S. A., Cerrito P. B. The role of microvascular damage in photodynamic therapy: the effect of treatment on vessel constriction, permeability, and leukocyte adhesion. Cancer Res. 1992;52(18):4914-4921.

   Not in our library

9. 9.

   Haimovici R., Kramer M., Miller J. W., Hasan T., Flotte T. J., Schomacker K. T., Gragoudas E. S. Localization of lipoprotein-delivered benzoporphyrin derivative in the rabbit eye. Curr Eye Res. 1997;16(2):83-90.

   Not in our library10.1076/ceyr.16.2.83.5088

10. 10.

    Henderson B. W., Dougherty T. J. How does photodynamic therapy work? Photochem Photobiol. 1992;55(1):145-157.

    Not in our library10.1111/j.1751-1097.1992.tb04222.x

11. 11.

    Korbelik M., Krosl G. Accumulation of benzoporphyrin derivative in malignant and host cell populations of the murine RIF tumor. Cancer Lett. 1995;97(2):249-254.

    Not in our library10.1016/0304-3835(95)03985-6

12. 12.

    Levy J. G. Photosensitizers in photodynamic therapy. Semin Oncol. 1994;21(6 Suppl 15):4-10.

    Not in our library

13. 13.

    Lin S. C., Lin C. P., Feld J. R., Duker J. S., Puliafito C. A. The photodynamic occlusion of choroidal vessels using benzoporphyrin derivative. Curr Eye Res. 1994;13(7):513-522.

    Not in our library10.3109/02713689408999883

14. 14.

    North J., Coombs R., Levy J. Photodynamic inactivation of free and cell-associated HIV-1 using the photosensitizer, benzoporphyrin derivative. J Acquir Immune Defic Syndr. 1994;7(9):891-898.

    Not in our library

15. 15.

    Richter A. M., Cerruti-Sola S., Sternberg E. D., Dolphin D., Levy J. G. Biodistribution of tritiated benzoporphyrin derivative (3H-BPD-MA), a new potent photosensitizer, in normal and tumor-bearing mice. J Photochem Photobiol B. 1990;5(2):231-244.

    Not in our library10.1016/1011-1344(90)80008-l

16. 16.

    Richter A. M., Waterfield E., Jain A. K., Allison B., Sternberg E. D., Dolphin D., Levy J. G. Photosensitising potency of structural analogues of benzoporphyrin derivative (BPD) in a mouse tumour model. Br J Cancer. 1991;63(1):87-93.

    Not in our library10.1038/bjc.1991.18

17. 17.

    Richter A. M., Waterfield E., Jain A. K., Canaan A. J., Allison B. A., Levy J. G. Liposomal delivery of a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD), to tumor tissue in a mouse tumor model. Photochem Photobiol. 1993;57(6):1000-1006.

    Not in our library10.1111/j.1751-1097.1993.tb02962.x

18. 18.

    Schmidt-Erfurth U., Flotte T. J., Gragoudas E. S., Schomacker K., Birngruber R., Hasan T. Benzoporphyrin-lipoprotein-mediated photodestruction of intraocular tumors. Exp Eye Res. 1996;62(1):1-10.

    Not in our library10.1006/exer.1996.0001

19. 19.

    Schmidt-Erfurth U., Hasan T., Gragoudas E., Michaud N., Flotte T. J., Birngruber R. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology. 1994;101(12):1953-1961.

    Not in our library10.1016/s0161-6420(13)31079-3

20. 20.

    Schmidt-Erfurth U., Hasan T., Schomacker K., Flotte T., Birngruber R. In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization. Lasers Surg Med. 1995;17(2):178-188.

    Not in our library10.1002/lsm.1900170207

21. 21.

    Star W. M., Marijnissen H. P., van den Berg-Blok A. E., Versteeg J. A., Franken K. A., Reinhold H. S. Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers. Cancer Res. 1986;46(5):2532-2540.

    Not in our library

22. 22.

    Wyss P., Tadir Y., Tromberg B. J., Liaw L., Krasieva T., Berns M. W. Benzoporphyrin derivative: a potent photosensitizer for photodynamic destruction of rabbit endometrium. Obstet Gynecol. 1994;84(3):409-414.

    Not in our library

23. 23.

    Young L. H., Howard M. A., Hu L. K., Kim R. Y., Gragoudas E. S. Photodynamic therapy of pigmented choroidal melanomas using a liposomal preparation of benzoporphyrin derivative. Arch Ophthalmol. 1996;114(2):186-192.

    Not in our library10.1001/archopht.1996.01100130180013

Cited by papers we hold 6

• Photodynamic Therapy—Current Limitations and Novel Approaches · 2021
  No notice
• PDGFRβ-specific affibody-directed delivery of a photosensitizer, IR700, is efficient for vascular-targeted photodynamic therapy of colorectal cancer · 2017
  Not checked
• Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions · 2017
  No notice
• Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies · 2015
  No notice
• Dye Sensitizers for Photodynamic Therapy · 2013
  No notice
• Bypass of Tumor Drug Resistance by Antivascular Therapy · 2003
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.